Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 9/20 | 0.44 |
| ▸ | NR4A2 | P43354 | 6/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6539118 | 0.86 | PPARD (0.49) | PPARDNR4A2 | |
| SCHEMBL6539587 | 0.86 | PPARD (0.44) | PPARDNR4A2ALDH1A1 | |
| SCHEMBL6538931 | 0.85 | PPARD (0.48) | PPARDNR4A2 | |
| SCHEMBL6540089 | 0.85 | PPARD (0.41) | PPARDNR4A2ALDH1A1MEN1HTT | |
| SCHEMBL6538879 | 0.83 | CA12 (0.43) | PPARDNR4A2 | |
| SCHEMBL6539128 | 0.83 | PPARD (0.42) | PPARDNR4A2ALDH1A1MEN1HTT | |
| SCHEMBL6540121 | 0.81 | PPARD (0.52) | PPARDNR4A2LMNA | |
| SCHEMBL6539901 | 0.81 | PPARD (0.44) | PPARDNR4A2 | |
| SCHEMBL6539106 | 0.80 | ALDH1A1 (0.44) | PPARDALDH1A1MEN1HTTKMT2A | |
| SCHEMBL6540515 | 0.80 | PPARD (0.53) | PPARDNR4A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040157891-A1 | Inhibitor of cox | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157891-A1 | Inhibitor of cox | PTGS1, PTGS2, PTGES2 | PPARD 1747/4885NR4A2 883/4885LMNA 2620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.